Dr. Geetika Dandamudi, Dr. Nivedita D Moulick, Dr. Harshal Bisen


Kawasaki disease (KD) is an acute systemic vascular disease that affects mostly medium sized and small vessels [1]. It is usually a self-limited disease with the highest incidence occurring in children under five years of age. We present a case of a 14 year old boy who presented with fever and rash in the lower part of the trunks and legs. Clinical examination revealed the presence of cervical lymphadenopathy, conjunctivitis and strawberry tongue. After making a clinical diagnosis of Kawasaki disease, the patient was successfully treated with intravenous immunoglobulin and aspirin. Proper diagnosis based on clinical findings, proper investigations and follow-ups are important to treat and prevent associated complications of the disease especially coronary aneurysm.


Kawasaki Disease (KD), Immunoglobulin, Aspirin, Coronary aneurysm.

Full Text:



Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006; 65: 936–41.

Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Japonica 1991; 41:785–97.

Weiss PF. Pediatric vasculitis. Pediatr Clin North Am.2012; 59:407–23.

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. . Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American heart association. Circulation 2017; 135:e927–99.

Sato YZ, Molkara DP, Daniels LB, et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol. 2013; 164: 58–63.

Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 2015; 11:819–25.

Suzuki H, Uemura S, Tone S, et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr. 1996; 155:291–6.

Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994; 139:71–8.

Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114:1708–33.

Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997; 131:888–93.

Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012; 161:506–12.

Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet 2012; 379:1613–20.

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008; 153:833–8.


  • There are currently no refbacks.